Literature DB >> 10788094

Accelerating acceptance.

G S DeCherney1.   

Abstract

Innovations are either accepted or rejected in large part because of their implementation--sometimes without regard to improvements over existing techniques. By understanding the dynamics of how innovations are adopted and by whom, physician executives will have insight into influencing others. All adopters are not created equal. They fall into five categories, beginning with those who embrace innovation, even seek it out. In any given organization, or the population in general, there are: (1) innovators (2.5 percent); (2) early adopters (13.5 percent); (3) early majority (34 percent); (4) late majority (34 percent); and (5) laggards (16 percent). As these categories imply, each group has specific personalities related to adopting innovations that can be identified and used to implement new policies and procedures. By identifying and encouraging innovators and early adopters to think outside the box and then gaining critical mass through the early majority, who also act as opinion leaders, organizations can accelerate the pace of adopting innovations. New processes are adopted when opinion leaders initiate new practices, whose results can be tangibly discerned by the majority of adopters.

Mesh:

Year:  1999        PMID: 10788094

Source DB:  PubMed          Journal:  Physician Exec        ISSN: 0898-2759


  3 in total

Review 1.  Future prospects in cardiac magnetic resonance imaging.

Authors:  Mark Doyle; Robert W W Biederman
Journal:  Curr Cardiol Rep       Date:  2003-01       Impact factor: 2.931

2.  Does the early adopter of drugs exist? A population-based study of general practitioners' prescribing of new drugs.

Authors:  Torben Dybdahl; Morten Andersen; Jens Søndergaard; Jakob Kragstrup; Ivar Sønbø Kristiansen
Journal:  Eur J Clin Pharmacol       Date:  2004-10-21       Impact factor: 2.953

3.  General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

Authors:  Torben Dybdahl; Morten Andersen; Jakob Kragstrup; Ivar Sønbø Kristiansen; Jens Søndergaard
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.